No Data
Ribomic and other ETC [stocks of interest viewed from volume change]
Stock closing prices compared to the previous day Volume *<4558>* Chukyo Pharmaceutical 229,235,302,700 *<4591>* Ribomic 106,233,886,9200 *<3604>* Kawamoto Industry 954,150,115,5400 *<2351>* ASJ 391,453,30500 *<7980>* Shigematsu Manufacturing 828,447,8300 *<3550>* Studio Atao 204,810,6900 *<5110>* Sumitomo Rubbers 1,769.5 20.56 697,600 *<3744>* Saios 39,629,218,500 *<
Eid, Enechange and others [Emerging Markets press release]
Acquired part of the Stocks of DFree, which is involved in the planning, development, and sales of the solution 'DFree' that alleviates the concerns and burdens of Yukaria excretion, and Mitsukari, which develops and operates the HRTech 'Mitsukari' that understands and analyzes the personality and compatibility of each individual to maximize the power of individuals and organizations. Recognized a subsidy benefit of 0.04 billion yen from Enechange as non-operating income. Significant exercise of subscription rights for the 17th subscription rights of Ribomik (with exercise price revision provisions) occurred on the 6th.
The Tokyo Stock Exchange Growth Index continues to rise, with a focus shifting toward interim purchases.
Tokyo Stock Exchange Growth Market Index 825.54 +3.18 / Volume 0.2 billion 1.01 million shares / Trading value 127.6 billion yen. Tokyo Stock Exchange Growth Market 250 Index 643.67 +2.73 / Volume 96.57 million shares / Trading value 94.9 billion yen. Today, the growth market showed a continuation of gains, with the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index both rising. The number of rising stocks was 261, declining stocks numbered 306, and there were 38 unchanged stocks. Today's growth market was strong. The previous day's (7th) USA market was soft.
Emerging Markets stock digest: BTM rebounded for the first time in six days and reached a daily maximum limit, while Ribomic significantly rebounded.
<303A> visumo 2340 -700 stop-limit. After updating the all-time high in the morning, it has shifted to a selling dominance due to a pause in buying. Visumo went public on December 26 last year, debuting at 1,036 yen, which is 34.5% above the offering price (770 yen). Since then, it has continued to hit the daily upper limit, and on the morning of the 8th, it surged to 3,110 yen, nearly three times the debut price. The operating profit Financial Estimates for the fiscal year ending March 2025 is expected to be 0.073 billion yen, which is a 291.8% increase compared to the previous term.
Individual stock information.
Justplan <4287.T> continued to rise for six days, remaining unchanged amid significant gains. A stock buyback limit of 600,000 shares (4.93% of issued shares excluding treasury stock) and a 200 million yen buyback program were established. The acquisition period is from January 8 to July 31. Additionally, 283,700 treasury shares currently held (2.23% of issued shares before retirement) will be retired effective January 15. McDonald's <2702.T> declined continuously. The preliminary monthly revenue for December was announced, showing same-store sales decreased by 0.4% compared to the same month last year, marking the fifth consecutive month of decline.
Ribomic soared sharply, reaching a temporary stop high, with a patent application resulting from joint research with Mitsubishi Corporation Life Sciences.
Ribomic <4591.T> surged, reaching a stop-high of 113 yen at one point, rising by 30 yen. After the close on the 7th, it was announced that the company succeeded in the creation and development of an 'anti-neutrophil elastase aptamer,' which serves as a candidate for Cosmetic raw materials, in joint research with Mitsubishi Corporation Life Sciences <8058.T>. The results were considered significant as the patent application was filed jointly with Mitsubishi Corporation Life Sciences at the patent office. Mitsubishi Corporation Life Sciences deals with food ingredients, health materials, Cosmetic raw materials, etc.
No Data